- Original Articles
- Open Access
A Critical Role of Nitric Oxide in Human Immunodeficiency Virus Type 1-Induced Hyperresponsiveness of Cultured Monocytes
© Molecular Medicine 1996
- Published: 1 July 1996
Human immunodeficiency virus type 1 (HIV-1) infection leads to a general exhaustion of the immune system. Prior to this widespread decline of immune functions, however, there is an evident hyperactivation of the monocyte/macrophage arm. Increased levels of cytokines and other biologically active molecules produced by activated monocytes may contribute to the pathogenesis of HIV disease both by activating expression of HIV-1 provirus and by direct effects on cytokine-sensitive tissues, such as lung or brain. In this article, we investigate mechanisms of hyperresponsiveness of HIV-infected monocytes.
Materials and Methods
The study was performed on monocyte cultures infected in vitro with a monocytetropic strain HTV-1ADA. Cytokine production was induced by stimulation of cultures with lipopolysaccharides (LPS) and measured by ELISA. To study involvement of nitric oxide (NO) in the regulation of cytokine expression, inhibitors of nitric oxide synthase (NOS) or chemical donors of NO were used.
We demonstrate that infection with HIV-1 in vitro primes human monocytes for subsequent activation with LPS, resulting in increased production of proinflammatory cytokines tumor necrosis factor (TNF) and interleukin 6 (IL-6). This priming effect can be blocked by Ca2+-chelating agents and by the NOS inhibitor l-NMMA, but not by hemoglobin. It could be reproduced on uninfected monocyte cultures by using donors of NO, but not cGMP, together with LPS.
NO, which is expressed in HIV-1-infected monocyte cultures, induces hyperresponsiveness of monocytes by synergizing with calcium signals activated in response to LPS stimulation. This activation is cGMP independent. Our findings demonstrate the critical role of NO in HIV-1-specific hyperactivation of monocytes.
Acquired immunodeficiency syndrome (AIDS) patients often show elevated circulating levels of pro-inflammatory monocyte-produced cytokines (monokines), particularly tumor necrosis factor (TNF) and interleukin 6 (IL-6) (1,2). These monokines, produced as a result of cell activation, can be expected to stimulate nearby uninfected cells, thus contributing to a generalized activation of the monocyte/macrophage arm of the immune system. In addition, pro-inflammatory cytokines have been shown to be powerful activators of human immunodeficiency virus type 1 (HIV-1) replication (3–5). Such abnormal activation is likely one of the important pathogenic factors in the development of AIDS (6,7). However, pathophysiological mechanisms that lead to enhanced cytokine production in AIDS remain unclear. Phenomenon of monocyte hyperactivation can be reproduced in vitro. Monocyte cultures infected in vitro with a monocytotropic HIV-1 strain produce significantly higher levels of pro-inflammatory monokines in response to stimulation than do similarly stimulated uninfected cultures (8,9), making such cultures a good model for studying events that lead to monokine hyperproduction in AIDS.
Recently, we demonstrated both induction of nitric oxide synthase (NOS) in and production of nitric oxide (NO) by HIV-1-infected monocytes (10). NO is a well-recognized mediator of cell activity, being involved in the regulation of various cellular functions (reviewed in Ref. 11), including gene expression (12–14). Many of the known inductive effects of NO have been attributed to its ability to activate guanylate cyclase and generate cGMP (15). Recent reports, however, suggest that NO may activate human peripheral blood monocytes (PBMC) (12,13,16) in a cGMP-independent way (13) and that it could be involved in the regulation of cytokine production by monocytes. We, therefore, examined whether NO produced by HIV-infected monocyte cultures is responsible for their hyperresponsiveness to stimulation. In this report, we demonstrate that NO enhances monocyte responses to stimulation by synergizing with Ca2+ signals. This effect is cGMP independent and most likely exerted in an autocrine fashion.
NO generators SNAP and NONO were purchased from Toronto Research Chemicals Inc. (Downsview, Ontario, Canada); guanylate cyclase inhibitor LY83583 was obtained from Research Biochemicals Inc. (Natick, MA, U.S.A.); other chemicals were from Sigma Chemical Co. (St. Louis, MO, U.S.A.).
Human monocytes were isolated from blood of healthy donors negative for HIV and hepatitis B antibodies by adherence to plastic as follows. Concentrated blood was diluted six times with Dulbecco’s Modified Eagle’s medium (DMEM, Sigma) and loaded on a Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) gradient. After a 20-min centrifugation at 200 × g at room temperature, the middle layer (PBMCs) was transferred to a new tube and gently washed three times with DMEM. Cells were then resuspended in DMEM supplemented with 10% heat-inactivated pooled human serum and 1% penicillin/streptomycin (Sigma) and counted. Cell suspension diluted to 5−8 × 106 cells/ml was placed in Primaria (Becton Dickinson, Franklin Lakes, NJ, U.S.A.) flasks and incubated 2 hr at 37°C. Adherent cells were washed three times with DMEM and left overnight at 37°C in DMEM supplemented with 10% human serum and 1% penicillin/streptomycin. Next day, cells were washed with cold phosphate-buffered saline (PBS, Sigma), incubated 3–5 min with cold 10 mM EDTA solution in PBS, and detached with a cell scraper. At that step, cells were counted, resuspended in DMEM + 10% human serum + 1% penicillin/streptomycin + 1 ng/ml M-CSF (Sigma) at 1 × 106 cells/ml, and placed into 24-well Primaria plates. Cells were allowed to differentiate for 7 days (half of the medium was changed on Day 3 and 5 after isolation) in the presence of M-CSF. Subsequent incubations for infection with HIV-1, cell stimulation, etc., were performed in the medium without M-CSF. Monocyte cultures prepared by this method were consistently >96% pure monocytes by the criteria of cell morphology on Wright-stained cytosmears and by nonspecific esterase assays.
Infection with HIV-1
Adherent monocytes cultured for 7 days were exposed to a monocytotropic viral strain HIV-1ADA at a concentration corresponding to reverse transcriptase (RT) activity of 2 × 105 cpm/ml. After an overnight incubation at 37°C, excess of the virus was washed away, and incubation was continued for 2–3 weeks. Culture medium was half-exchanged every 2–3 days.
Reaction mixture (50 µl) containing 10 µl of supernatant from HIV-infected culture (precleared from cell debris by centrifugation at 5000 × g for 5 min), 50 mM Tris (pH 7.8), 20 mM KCl, 5 mM MgCl2, 1 mM DTT, 0.2 OD/ml poly(A), 0.2 OD/ml oligo(dT)12–18, 0.1% Triton X-100, and 40 µCi/ml 3H-TTP (76 Ci/mmol; DuPont, Wilmington, DE, U.S.A.), was incubated 2 hr at 37°C. Five microliters of the reaction mixture were then spotted onto the DE81 (Whatman, Hillsboro, OR, U.S.A.) ion exchange paper, air dried, and washed five times with 5% Na2HPO4, followed by rinsing with distilled water. Air-dried filters were covered with scintillation fluid in Flexi Filter plate (Packard, Downers Grove, IL, U.S.A.) and counted in a Top Count Microplate Counter (Packard). Results are expressed as counts per minute per 1 ml of culture supernatant (cpm/ml).
HIV-1-infected cultures were incubated until RT activity in the culture supernatants reached 0.7−1.1 × 106 cpm/ml (6–10 days). Replicate cultures of control (uninfected) cells were maintained under similar conditions. Treatments were performed in three independent wells for each combination of agents. Usually, all compounds were added simultaneously at the time when RT reached an indicated level and were present throughout the duration of an experiment (24–48 hr).
TNF and IL-6 in culture supernatants were determined by Medgenix EASIA System (Incstar Corp., Stillwater, MN, U.S.A.) utilizing non-neutralizing monoclonal antibodies in the development of immunoassay and thus allowing detection of both free and soluble receptor-bound cytokines.
Inhibitors of NOS Reduce Amounts of Pro-Inflammatory Cytokines Produced by LPS-Stimulated HIV-1–Infected Monocyte Cultures
Recently, we have demonstrated that infection with HIV-1 induces expression of iNOS in human monocytes (10). To determine whether NO plays a role in establishing the hyperactivation phenotype in HIV-1-infected monocytes, we measured cytokine production in LPS-stimulated, HIV-infected monocyte cultures in the presence of NOS inhibitor l-NMMA. This inhibitor significantly suppressed the LPS-induced superproduction of TNF by HIV-infected monocytes, resulting in expression levels close to those observed in similarly stimulated uninfected cultures (Fig. 1 A–C). A similar effect was seen with other inhibitors of NOS l-NAME and aminoguanidine (resufts not shown). Inhibition was not observed with d-NMMA (Fig. 1), a noninhibitory analog of l-NMMA. NOS inhibitors did not affect levels of TNF produced by LPS-stimulated monocyte cultures (data not shown). This is in agreement with the previously demonstrated failure of LPS to induce NOS in human monocytes (10,17) and argues against the recently suggested role for NO in LPS-mediated monocyte activation (16). Nitric oxide, therefore, seems to be one of the major factors that regulate overexpression of cytokines by HIV-infected monocytes.
NO Donors Enhance LPS-Induced Production of TNF by Human Monocytes
Autocrine Mechanism of NO Activity in HIV-infected Monocytes
NO is a potent local messenger molecule, capable of rapid migration from cell to cell, thus exerting its effects in both autocrine and paracrine fashion (18); the paracrine mode is, however, the major mechanism of NO effects (19). To determine its level of action in HIV-1-infected monocyte cultures, we used a high-molecular weight scavenger of NO, hemoglobin, which is not freely exchanged between the intra- and extracellular fluids and therefore mainly affects extracellular levels of NO (20). Hemoglobin did not have any significant effect on TNF production by HIV-1-infected, LPS-stimulated monocyte cultures (Fig. 1). Hemoglobin, however, decreased the activating effect of NO-generating compounds on LPS-stimulated monocytes (not shown), demonstrating its potency as an extracellular NO scavenger. This experiment suggests that HIV-1–induced NO exerts its effects mostly in an autocrine fashion that does not depend on an extracellular phase. This explanation seems even more likely given a relatively low NO output by HIV-infected monocytes, thus increasing chances for its consumption within the producer cell. This result differs from the one reported by Zinetti et al. (16), who observed similar inhibition of TNF production by hemoglobin and by l-NMMA in LPS-stimulated mixed populations of PBMCs. We explain this difference by the contribution to NO production by non-monocytic cells (e.g., B lymphocytes ) in PBMCs, since we never observed NO effects in LPS-stimulated uninfected monocyte cultures. A possibility remains that other NOX species not scavenged by hemoglobin are produced intracellularly by HIV-infected monocytes in our experimental setting and that these are responsible for the observed effects. Although we cannot formally discount this possibility, the fact that HIV-1 produces the same effect on LPS-induced cytokine expression as addition of NO generators, and that the effect of NO generators can be blocked by hemoglobin, argues against this explanation.
NO Synergizes with Calcium in the Induction of Cytokines
Although results presented above demonstrate that NO amplifies Ca2+-induced expression of cytokines, they do not prove that calcium is involved in NO-mediated amplification of LPS stimulation of HIV-1-infected monocytes. To test this hypothesis, we stimulated HIV-1-infected and control monocyte cultures with LPS in the presence of the Ca2+ chelators, EGTA, which binds extracellular calcium, and BAPTA, which efficiently diffuses into the cell and reduces intracellular concentrations of Ca2+. Both agents reduced production of TNF by uninfected LPS-stimulated monocytes by about 30% (Fig. 4B). The effect of the compounds on HIV-infected cultures was substantially greater, completely eliminating HIV-specific superproduction of TNF (Fig. 4B). Similar results were obtained with uninfected cultures stimulated with LPS in the presence of the NO generator SNAP. Both EGTA and BAPTA eliminated NO-specific amplification of TNF production by monocyte cultures (Fig. 4B). This experiment suggests that while Ca2+-mediated signaling is only a minor component of LPS-specific induction of cytokines in human monocytes (25), it is the major target for NO-regulated amplification.
NO Activates Monocytes by a cGMP-Independent Mechanism
Many of the known inductive effects of NO have been attributed to its ability to activate guanylate cyclase and generate cGMP (15). Therefore, we examined whether the cell pervious cGMP analogue, 8-Br-cGMP, could also amplify LPS-induced TNF production by human monocytes. No effect of 8-Br-cGMP at concentrations 10 and 100 µM on TNF levels was observed (data not shown), thus suggesting a cGMP-independent mechanism of NO-mediated potentiation of LPS effect. This was further supported by experiments with LY-83583, an inhibitor of guanylate cyclase (26). When used at the 10 µM concentration, this inhibitor did not diminish the NO-mediated increase of LPS-induced TNF production in HIV-infected monocyte cultures (not shown).
NO Produced in HIV-infected Monocyte Cultures Does Not Provide Anti-Viral Defense
Since NO was shown to have anti-viral activity (27,28), including recently demonstrated inhibitory effect on a murine retrovirus (29), we investigated the possibility that NO production could be a defense reaction of monocytes to HIV-1 infection. Surprisingly, presence of l-NMMA in the culture medium had only a minor (less than 20%) effect on HIV-1 replication, and this effect was inhibitory rather than enhancing (results not shown). This result is counterintuitive, but we think the explanation for this lack of anti-viral activity of NO lies in the low levels of this factor produced by HIV-infected monocyte cultures. These levels are insufficient to exert any direct anti-viral effect but are adequate to affect the state of cell activation, thus indirectly enhancing HIV-1 replication.
In this paper, we demonstrated a critical role of NO in establishing an abnormal hyperactivated phenotype of HIV-1-infected monocytes. Our recent work (10) has shown elevated levels of NOS RNA and NO in HIV-1-infected monocyte cultures. This was an unexpected discovery, since human monocytes, in contrast to their murine counterparts, do not normally respond to activation or infection by substantially increasing NO production (17,30). Even these unusual induced levels of NO production by HIV-infected human monocytes were about 10 times lower than those typically achieved by murine macrophages stimulated with interferon-γ and LPS (31). These lower levels probably cannot account for pathological effects on bystander cells, in the manner shown for NO-mediated neurotoxicity in mice (32), so this mechanism of direct NO-mediated toxicity seems unlikely in HIV-1 infection. However, as we show in this paper, intracellular concentrations of NO in HIV-1-infected monocytes are sufficient to amplify the stimulatory effects of low doses of LPS. Since opportunistic infections are common in HIV-1-infected patients, the two-signal mechanism (i.e., mediated by LPS and NO) of hyperactivation of HIV-infected macrophages would appear likely.
Our results demonstrate that NO can stimulate monocytes by amplifying the calcium signals, thus resembling the synergism between NO and Ca2+ in the activation of immediate-early genes in neuronal cells (14). This suggests that a similar cooperation between HIV-induced NO and LPS-evoked calcium elevation might eventually lead to the enhanced expression of the cytokine genes. In contrast to neuronal cells (14), however, NO effects in monocytes are cGMP-independent. A similar cGMP-independent activation of human PBMC by NO-generating compounds was described by Lander et al. (13). The signal transduction pathways linking NO to calcium-mediated activation of TNF expression in HIV-infected monocytes are the subject of ongoing studies in our laboratories.
The authors wish to thank K. Manogue for critical reading of the manuscript and helpful comments, and A. Cerami for continued encouragement and support. This work was supported in part by the AmFAR Grant 02059-15-RGR (MB) and by funds from The Picower Institute for Medical Research.
- Gurram M, Chirmule N, Wang XP, Ponugoti N, Pahwa S. (1994) Increased spontaneous secretion of interleukin 6 and tumor necrosis factor alpha by peripheral blood lymphocytes of human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 13: 496–501.PubMedGoogle Scholar
- Emilie D, Fior R, Jarrousse B, et al. (1994) Cytokines in HIV infection. Int. J. Immunopharmacol. 16: 391–396.View ArticlePubMedGoogle Scholar
- Clouse KA, Powell D, Washington I, et al. (1989) Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J. Immunol. 142: 431–6438.PubMedGoogle Scholar
- Poli G, Fauci AS. (1992) The role of monocyte/macrophages and cytokines in the pathogenesis of HIV infection. Pathobiology 60: 246–251.View ArticlePubMedGoogle Scholar
- Poli G, Fauci AS. (1993) Cytokine modulation of HIV expression. Semin. Immunol. 5: 165–173.View ArticlePubMedGoogle Scholar
- Tyor WR, Glass JD, Griffin JW. (1992) Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann. Neurol. 31: 349–360.View ArticlePubMedGoogle Scholar
- Wesselingh SL, Power C, Glass JD, et al. (1993) Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann. Neurol. 33: 576–582.View ArticlePubMedGoogle Scholar
- Schmidtmayerova H, Nottet HSLM, Nuovo G, et al. (1996) HIV-1 infection alters chemokine β peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc. Natl. Acad. Sci. U.S.A. 93: 700–704.View ArticlePubMedPubMed CentralGoogle Scholar
- Nottet HSLM, Jett M, Flanagan CR, et al. (1995) A regulatory role of astrocytes in HIV-1 encephalitis. An overexpression of eicosanoids, platelet-activating factor, and tumor necrosis factor-α by activated HIV-1-infected monocytes is attenuated by primary human astrocytes. J. Immunol. 154: 3567–3581.PubMedGoogle Scholar
- Bukrinsky MI, Nottet HS, Schmidtmayerova H, et al. (1995) Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J. Exp. Med. 181: 735–745.View ArticlePubMedGoogle Scholar
- Bredt DS, Snyder SH. (1994) Nitric oxide: a physiologic messenger molecule. Annu. Rev. Biochem. 63: 175–195.View ArticlePubMedGoogle Scholar
- Lander HM, Sehajpal PK, Novogrodsky A. (1993) Nitric oxide signaling: A possible role for G proteins. J. Immunol. 151: 7182–7187.PubMedGoogle Scholar
- Lander HM, Sehajpal P, Levine DM, Novogrodsky A. (1993) Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J. Immunol. 150: 1509–1516.PubMedGoogle Scholar
- Peunova N, Enikolopov G. (1993) Amplification of calcium-induced gene transcription by nitric oxide in neuronal cells. Nature 364: 450–453.View ArticlePubMedGoogle Scholar
- Stamler JS. (1995) Redox signaling: Nitrosylation and related target interactions of nitric oxide. Cell 78: 931–936.View ArticleGoogle Scholar
- Zinetti M, Fantuzzi G, Delgado R, Di Santo E, Ghezzi P, Fratelli M. (1995) Endogenous nitric oxide production by human monocytic cells regulates LPS-induced TNF production. Eur. Cytokine Netw. 6: 45–48.PubMedGoogle Scholar
- Padgett EL, Pruett SB. (1992) Evaluation of nitrite production by human monocyte-derived macrophages. Biochem. Biophys. Res. Commun. 186: 775–781.View ArticlePubMedGoogle Scholar
- Moncada S, Palmer RMJ, Higgs EA. (1991) Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43: 109–142.PubMedGoogle Scholar
- Lancaster JR. (1994) Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 91: 8137–8141.View ArticlePubMedPubMed CentralGoogle Scholar
- Stuehr DJ, Nathan CF. (1989) Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169: 1543–1555.View ArticlePubMedGoogle Scholar
- Mannick JB, Asano K, Izumi K, Kieff E, Stamler JS. (1994) Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79: 1137–1146.View ArticlePubMedGoogle Scholar
- Lee CG, Demarquoy J, Jackson MJ, O’Brien WE. (1994) Molecular cloning and characterization of a murine LPS-inducible cDNA. J. Immunol. 152: 5758–5767.PubMedGoogle Scholar
- Letari O, Nicosia S, Chiavaroli C, Vacher P, Schlegel W. (1991) Activation by bacterial lipopolysaccharide causes changes in the cytosolic free calcium concentration in single peritoneal macrophages. J. Immunol. 147: 980–983.PubMedGoogle Scholar
- Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP. (1990) Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2+-ATPase. Proc. Natl. Acad. Sci. U.S.A. 87: 2466–2470.View ArticlePubMedPubMed CentralGoogle Scholar
- Hurme M, Viherluoto J, Nordstrom T. (1992) The effect of calcium mobilization on LPS-induced IL-1β production depends on the differentiation stage of the monocytes/macrophages. Scand. J. Immunol. 36: 506–511.View ArticleGoogle Scholar
- Mulsch A, Luckhoff A, Pohl U, Busse R, Bassenge E. (1989) LY-83583 (6-amilino-5,8-quinolinedione) blocks nitro vasodilator-induced cyclic GMP increases and inhibition of platelet activation. Naunyn Schmiedeberg’s Arch. Pharmacol. 340: 119–125.Google Scholar
- Croen KD. (1993) Evidence for an antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J. Clin. Invest. 91: 2446–2452.View ArticlePubMedPubMed CentralGoogle Scholar
- Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD. (1993) Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 261: 1445–1448.View ArticlePubMedGoogle Scholar
- Akarid K, Sinet M, Desforges B, Gougerot-Pocidalo MA. (1995) Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo. J. Virol. 69: 7001–7005.PubMedPubMed CentralGoogle Scholar
- Schneemann M, Schoedon G, Hofer S, Blau N, Guerrero L, Schaffner A. (1993) Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J. Infect. Dis. 167: 1358–1363.View ArticlePubMedGoogle Scholar
- Lorsbach RB, Murphy WJ, Lowenstein CJ, Snyder SH, Russell SW. (1993) Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between in-terferon-gamma and lipopolysaccharide. J. Biol. Chem. 268: 1908–1913.PubMedGoogle Scholar
- Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. (1993) Mechanisms of nitric-oxide-mediated neurotoxicity in primary brain cultures. J. Neurosci. 13: 2651–2661.View ArticlePubMedGoogle Scholar